Most stem cell-based therapeutic products are investigational and still require preclinical and clinical studies to support their many novel therapeutic uses. Medical researchers believe that stem cell therapy has the potential to dramatically change the treatment of human disease. A number of adult stem cell therapies already exist, particularly bone marrow transplants that are used to treat leukemia.
Hematopoietic stem cell transplantation is routinely used as part of the treatment strategy for some malignancies and genetic diseases. Stem cell-based therapies plays a important role for the treatment of serious diseases and injuries.
Specific technical issues relating to the transplantation of human cells in animals, new delivery procedures, and laborious methods to categorized transplanted cells can present further challenges in the design and execution of preclinical animal studies for stem cell-based therapeutic products.
Hematopoietic stem cell transplantation remains a dangerous procedure with many possible complications; it has traditionally been reserved for patients with life-threatening diseases. While occasionally used experimentally in nonmalignant and nonhematologic indications such as severe disabling auto-immune disease and cardiovascular disease, the risk of fatal complications appears too high to gain wider acceptance. Journal of Clinical case reports publishes case reports related to Stem cells Research and Therapy.
OMICS Group is a scientific organization and online publishing house that drives the progress of research through freely available open access journals and international conferences. With 700+ peer-reviewed journals in its list and many expert reviewers and scientists in its editorial board OMICS Group is among the best open access publishers of the world. Also, OMICS Group organizes more than 3000+ International Scientific Conferences annually and provides eBooks, and additional services such as ScholarsCentral. OMICS Group has got support of more than 1000+ Scientific associations, 50,000+ editorial board members and 15 million readers.
Last date updated on April, 2024
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi